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Background: Postoperative nausea and vomiting (PONV) remains a challenge for patients and health professionals 
despite various newly developed prophylactic interventions. We reviewed the efficacy and safety of ramosetron in 
randomized controlled trials (RCTs) for the prevention of PONV. 
Methods: We reviewed 18 randomized controlled trials investigating the efficacy and safety of ramosetron in 
comparison with placebo or any other drugs. Relevant studies were searched in the MEDLINE, SCOPUS, and 
the Cochrane database libraries. Our end points of concern were prevention of PONV and adverse effects as 
dichotomous data. 
Results: The prophylactic effect of 0.3 mg ramosetron was observed in early PON (relative risk, RR: 0.4; 95% CI 0.3-
0.6), early POV (RR: 0.3; 95% CI 0.1-0.6), late POV (RR: 0.3; 95% CI 0.1-0.6), but not late PON (RR: 0.7; 95% CI 0.5-
1.0). Compared with placebo, the efficacy of 0.3 mg ramosetron in adults and 6 μg/kg in children were consistently 
beneficial in preventing PONV overall (RR: 0.4; 95% CI: 03-0.6). The effects of 0.3 mg ramosetron and 3 mg 
granisetron were similar. No serious side effects or adverse events resulted from ramosetron and other active drugs, 
and incidence was similar to those of the placebo group. 
Conclusions: Ramosetron is effective and safe in children and adults without serious adverse effects compared 
with placebo or other active drugs, as shown in pooled data of RCTs, in terms of the prevention of PONV.  (Korean J 
Anesthesiol 2011; 61: 405-412)
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Introduction
Postoperative nausea and vomiting (PONV) is one of 
the most common complaints following anesthesia and 
serious complications of clinical concern in the postoperative 
period [1,2]. It is often associated with increased morbidity 
of postoperative bleeding, wound dehiscence, pulmonary 
aspiration of gastric contents, fluid and electrolyte imbalance, 
dehydration, delayed hospital discharge, unexpected hospital 
admission, and decreased satisfaction in surgical patients [3]. 
PONV without prophylaxis is a serious and common cause 
of significant problems, especially in children [4,5]. Reported 
incidence of overall PONV is between 20 and 30% but can 
increase up to 80% in high-risk patients. PONV seems to be 
considered multi-factorial, involving anesthetic, surgical, 
and individual risk factors [6]. Pharmacological and non-
pharmacological methods are currently available to prevent 
PNOV.
Several antiemetics are used for the prevention or relief of 
PONV [7-9]. Consequently, even children better tolerated PONV 
with antiemetics, as these drugs lessened the risk and distress 
associated with it [4,5,10]. PONV and discomfort needs to be 
properly controlled to relieve patients’ suffering and achieve 
better outcomes. 
Among antiemetics, ramosetron, a selective serotonin 5-hydro  -
xytryptamine type 3 (5-HT3) receptor antagonist, has better 
inhibitory activities than those of formerly available antagonists 
such as ondansetron, granisetron, and tropisetron. Ramosetron 
is more potent and has longer-lasting antiemetic effects than 
older agents because of a slower rate of dissociation from the 
target receptor and higher binding affinity [11]. This class of 
selective 5-HT3 receptor antagonists prevents serotonin binding 
to 5-HT3 receptors at the ends of the vagal afferent branches, 
which directly signals the vomiting center in the medulla 
oblongata and in the chemoreceptor trigger zone of the brain 
[11,12]. 
The object of this quantitative systemic review was to define 
the evidence in published randomized controlled trials (RCTs) 
concerning the efficacy and safety of ramosetron in preventing 
PONV. We extensively reviewed the literature and evaluated 
the pharmacologic efficacy and safety of ramosetron in the 
prevention of PONV. 
Materials and Methods
This study was undertaken following the guidance of the 
preferred reporting items for systemic reviews and meta-
analysis (PRISMA) statement for performing quantitative 
systemic reviews [13,14]. 
Systematic search and strategy
A systemic search of the relevant literature was performed 
without language limitation but restricted to RCTs available 
in English. We mainly explored MEDLINE using PUBMED 
and SCOPUS, the Cochrane database library using references 
found in reviews, or initially identified articles which were 
also used for further articles related to the topic. Published 
articles contained key words such as “ramosetron,” “PONV,” 
“nausea,” “vomiting,” “postoperative,” “postoperative nausea 
and vomiting,” and “antiemetics” in their titles or abstracts, and 
electronic searches were conducted until November 2010. The 
search strategy consisted of a combination of free text words as 
follows: “postoperative OR postanaesthetic OR postanesthetic 
OR surgical” AND “nausea OR emesis OR vomiting OR 
retching” AND “ramosetron OR nausea” . A copy of each paper 
was retrieved for final assessment of eligibility.
Inclusion and exclusion criteria
Inclusion criteria were as follows: (1) the study was published 
as a full report of randomized controlled trials that tested the 
efficacy and safety of ramosetron compared with placebo or 
any other drugs as control in the prophylaxis of PONV following 
general anesthesia; (2) the placebo was identical in appearance 
and had no active drugs; and (3) the subjects were human 
(adults and children), and all participants irrespective of sex, 
age, surgery, or age were considered. We did not include data 
from abstracts, posters, case reports, comments or letters to the 
editor, reviews, and animal studies. No attempts were made to 
obtain unpublished studies, nor did we request unpublished 
data from the company developing the drug.
Definition of relevant outcome data
Nausea was defined as subjectively having unpleasant 
feeling associated with being sick or awareness of the urge to 
vomit. Vomiting was defined as a forceful expulsion of gastric 
contents or retching that was defined as labored spasmodic, 
rhythmic contraction of the respiratory muscles without 
expulsion of gastric contents. PONV included both nausea and 
vomiting [15]. 
Many studies revealed evidence for different underlying 
PONV risk factors in children and the need for higher doses of 
prophylactic antiemetics in children, necessitating different 
preoperative risk scores than those used for adults [16]. Therefore, 
we separated the relevant outcome data for children and adults 
and analyzed accordingly. 407 www.ekja.org
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Data extraction and quality assessment
We retrieved patient information, including the type of 
surgery, drug dose, and route of administration, comparators, 
study end-points, adverse effects, and rescue medication. The 
outcome data of PONV at three time points were extracted: 
early period (0-6 h), late period (≥ 6 h), and the overall period 
(0-24/48 h). Antiemetic effects of early and late periods were 
only analyzed for 0.3 mg ramosetron compared data because of 
inconsistencies or absences in reporting. When PONV events 
were presented at different times, we selected cumulative values 
near postoperative 6 hours and 24/48 hours. PONV events, 
including retching, were the primary outcomes, and incidence 
of adverse effects and the use of rescue medication were 
secondary outcomes. The primary and secondary outcomes 
were separately compiled. A single investigator examined and 
scored the retrieved reports using the five-point Oxford scale 
for validity assessment (randomization 0-2, blinding 0-2, 
description of withdrawals and dropouts 0-1) [17]. 
Quantitative analysis
Collected data were recorded on formalized sheets, and 
values originally provided as percentages were converted into 
actual corresponding numbers (of patients and incidence) for 
analysis where needed. We computed the relative risk (RR) with 
corresponding 95% confidence intervals (CIs) for dichotomous 
outcome data using a fixed-model, if no heterogeneity was 
present. Otherwise, a random-effects model was applied. Heter-
ogeneity was judged with the I
2-test, assuming heterogeneity 
if an I
2 value of more than 25% was observed. When the 95% 
CI did not include the value 1.0, we assumed a statistically 
significant difference between an intervention and control. 
Subgroup analysis of the following items was performed to 
investigate relevant clinical heterogeneity: different doses, time 
of application, route of administration, and active-controlled 
versus placebo-controlled trials. We calculated the number 
needed to treat or to harm (NNT) as a useful estimate measure 
of the clinically significant effect. NNT is the number of patients 
that must be treated with an experimental intervention to 
achieve a particular result (beneficial or harmful) in one of them 
which would not have been the case had they all received the 
control intervention (placebo). A potential publication bias was 
explored with asymmetry of overall period PONV data using a 
funnel plot. Statistical analysis was performed using MIX 2.0 
for Windows that was developed and validated by Leon Bax of 
the Department of Medical Informatics of Kitasato University 
in Japan [18,19]. Incidences of PONV with various doses of 
ramosetron were compared using Fisher's exact test using SPSS 
13.0 for Windows, and P < 0.05 was considered significant. 
Results
We identified 34 potential articles of randomized controlled 
trials through key words and free text words (Fig. 1). Eventually a 
total of 1888 subjects in 18 studies were included in the present 
systemic review. Sixteen pertinent studies were excluded. One 
of them had no accessible dichotomous data on PONV, and 4 
trials were not available or inappropriate for use in this review 
(Table 1, studies 2, 3, 7, 22) [8]. Eleven articles were reviews, 
comments, or studies with inappropriate settings. The details of 
the trials are presented in Table 1. 
The median quality of score was 3 (range: 2-5). Nineteen 
trials were in adults, and three were in children (range: 4-10 
years). Some trials compared different doses of the same drug, 
and different regimens were evaluated such as oral and IV 
administrations, fixed doses (full milligram), and variable doses 
(microgram per kilogram body weight). Ramosetron was given 
at the end of surgery in 17 trials, while it was administered 30 
minutes before the end of surgery in 1 trial. It was given before 
induction in four trials and after induction in 1 trial. 
Ramosetron dose (studies 8, 10, 12, 14)
The incidence of overall PONV events (0-24/48 hours after 
anesthesia) was 56 ± 15 (%, mean ± SD) with placebo, 49 ± 
16 with 0.15 mg ramosetron, 16 ± 7 with 0.3 mg ramosetron, 
and 12 ± 5 with 0.6 mg ramosetron. There was no significant 
difference between placebo and 0.15 mg ramosetron or 
between 0.3 mg and 0.6 mg ramosetron. The most frequently 
used regimen of ramosetron was 0.3 mg IV as a minimum 
effective dose; increasing the dose to 0.6 mg provided no further 
benefit. In children, 6 μg/kg IV was the most effective dose (Table 1) 
[5,20-26].
Fig. 1. Flow chart of article selection according to the guideline of 
PRISMA statement. RCTs: randomized, controlled, trials.408 www.ekja.org
Vol. 61, No. 5, November 2011 Ramosetron for the prevention of PONV
Table 1. Summary of Randomized, Blinded, Controlled Trials   
Study ID   
Intervention/
Control   
n 
PON 
(early)     
POV 
(early)
PON 
(late)
POV 
(late)  
PONV 
(overall)
Rescue-
need
AE Surgery Time  Remarks
Choi et al. [29] P                 70 49 37 Cardiac surgery     E
Study 1 O4 + 12 (PCA)      71 33 24
R0.3             70 38 30
R0.3 + 0.6 (PCA)    68 24 20
Ryu et al. [30]      O4 40 17 7 10 0 17 Laparoscopic  E 0-2 h: early period         
Study 2         O8  40 8 3 4 0 8 Cholecystectomy
R0.3              40 8 1 4 0 8
Jeon et al. [34]     R0.3               60 8 4 26 Thyroidectomy     After IND  
Study 3         D8        60 21 16 22
R0.3 + D8           60 6 3 22
Kim et al. [35]      P                  54 34 17 24 18 37 22 18 Gynecological      E 0-6 h: early period    
Study 4         O8     54 19 8 17 8 24 16 17 Surgery           
R0.3              54 18 4 22 7 27 8 20
Lee et al. [36]      P  40 13 6 12 10 5 0 Gynecological  Before 0-1 h: early period 
Study 5         R0.1 (PO)          40 4 4 6 7 2 1 Surgery IND 
R0.3              40 4 3 5 2 2 1
Choi et al. [37]
Study 6 
O4 + 12 (PCA) +
  R0.3 (24 h)
47 23 9 25 11 18 27 Spine surgery   
   
E  0-1 h: early period
        R0.3 + 0.3 (24 h)       47 31 2 25 5 16 14
Lee et al. [38]       P    77 57 41 12 Breast surgery      E 
Study 7         R0.1              79 22 12 20
R0.1 (PO)           80 20 4 14
Fujii et al. [24]     P  20 10 Termination of    E
Study 8         R0.15              20 9 Pregnancy 
R0.3               20 3
R0.6               20 2
Fujii et al. [31]     P  30 14 6 Breast surgery        E  
Study 9         G3 30 5 4
R0.3               30 3 6
Fujii et al. [39]      P 20 15 Total hip            E         
Study 10        R0.15             20 14 Replacement
R0.3               20 5
R0.6               20 4
Fujii et al. [23]      P    25 15 6 4 Middle ear surgery    Before  IND        
Study 11        R0.15             25 13 5 5
R0.3               25 3 0 4
R0.6               25 2 0 4
Fujii et al. [25]      P   25 10 Laparoscopic E
Study 12        R0.15             25 8 Cholecystectomy 
R0.3               25 2
R0.6               25 2
Lee et al. [32]      P 41 25 13 13 Thyroidectomy  Before IND         
Study 13        G20 µg/kg 36 11 4 11
R4 µg/kg 36 18 7 15
Fujii et al. [26]     P     20 12 Thyroidectomy  E
Study 14       R0.15              20 10
R0.3               20 3
R0.6               20 2
Fujii et al. [40]     G3  40 7 6 Thyroidectomy     E         
Study 15       R0.3              40 5 5
Fujii et al. [22]     P                 30 9 11 8 10 Gynecological  E 0-3 h: early period   
Study 16       R0.15             30 9 9 8 8 Surgery 
R0.3               30 2 3 3 2
R0.6               30 2 2 2 2
Fujii et al. [41]     G3 50 7 7 Middle ear surgery          Before IND 
Study17  R0.3               50 5 6
Fujii et al. [28] G3  40 6 Laparoscopic            E  
Study 18        R0.3               40 3 Cholecystectomy
Fujii et al. [33]     G2.5               60 5 5 5 6 Gynecological  E 0-3 h: early period 
Study 19        R0.3              60 3 3 3 4 Surgery
Fujii et al. [5]     P   20 15 6 Strabismus surgery E Children
Study 20       R3 µg/kg 20 13 5 Only retching and    
R6 µg/kg 20 2 0 Vomiting
R12 µg/kg 20 2 0
Fujii et al. [20]     P     20 14 6 Tonsillectomy E Children
Study 21       R3 µg/kg 20 13 5 Only retching and    
R6 µg/kg 20 2 0 Vomiting
R12 µg/kg 20 2 0
Fujii et al. [21]      G40 µg/kg 40 6 Strabismus surgery   E  Children   
Study 22        R6 µg/kg 40 4 Only retching and    
Vomiting 
P: placebo,O4, 8: ondansetron 4, 8 mg, O12 (PCA): ondansetron 12 mg through PCA, R0. 0.15, 0.3, 0.6: ramosetron 0.15, 0.3, 0.6 mg, R0.6 (PCA): 
ramosetron 0.6 mg through PCA, R0.1: ramosetron 0.1 mg per oral, R0.3 (24 h): ramosetron injected at 24 hours after surgery, G2.5, 3: grainsetron 
2.5, 3 mg, D8: dexamethasone 8 mg, R4 µg/kg: ramosetron 0.24 mg (assuming an average body weight of 60 kg) and was included in R0.3, PON: 
postoperative nausea, POV: postoperative vomiting (including retching), PONV: postoperative nausea and vomiting, early period: <6 hours, 
late: 1-24 hours, AE: Adverse effects. E: IV at end of surgery, IND: induction.   409 www.ekja.org
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0.3 mg ramosetron versus placebo 
All trials (studies 4, 5, 16) showed a benefit of 0.3 mg 
ramosetron in the prevention of early PON (RR: 0.4; 95% CI, 
0.3-0.7), early POV (RR: 0.3; 95% CI 0.2-0.6), and late POV (RR: 
0.3; 95% CI, 0.1-0.6), but not late PON (RR: 0.6; 95% CI, 0.3-
1.2). Ramosetron at this dose was compared with placebo in 9 
trials of overall PONV, 5 trials of rescue-need, 5 trials of adverse 
effects in adults, and 2 trials of overall PONV and rescue-
need in children (studies 20, 21, Table 1). All results in overall 
PONV and rescue-need showed a significant effect of 0.3 mg 
ramosetron in adults and 6 µg/kg in children because the 95% 
CI did not include the value of 1.0 (Fig. 2). Comparing 0.3 mg 
ramosetron and placebo, RR in adults was 0.5 (95% CI, 0.3-0.6), 
and NNT was 3.3 in overall PONV. In rescue-needed trials, RR 
was 0.5 (95% CI, 0.3-0.8), and NNT was 5. In trials with adverse 
effects, RR was 1.2 (95% CI, 0.8-1.6), and NNT was 33 without 
significant difference (Fig. 3). As no heterogeneity was found 
except in overall PONV when comparing 0.3 mg ramosetron 
and placebo, a subgroup analysis of different time points of 
ramosetron administration was performed. However, different 
time points did not affect heterogeneity. 
0.3 mg ramosetron versus 3 mg granisetron 
0.3 mg ramosetron was compared with 3 mg granisetron in 
4 trials of overall PONV and 3 trials of adverse effects in adults 
(Table 1). RR was 0.6 (95% CI, 0.3-1.2) in overall PONV and 
1 (95% CI, 0.5-1.8) in adverse effects. Therefore, no significant 
difference was found between 0.3 mg ramosetron and 3 mg 
granisetron. 
Fig. 2. Annotated forest plot (overall PONV: 0.3 mg ramosetron in adults and 6 μg/kg in children, studies 20, 21) depicted individual trials as 
filled squares with relative size of weights and horizontal bars as the confidence interval. The bottom diamond shape indicates the pooled 
value.
Fig. 3. Annotated forest plot (rescue-need: 0.3 mg ramosetron in adults and 6 μg/kg in children (studies 20, 21) depicted individual trials as 
filled squares with relative size of weights and horizontal bars as the confidence interval. The bottom diamond shape indicates the pooled 
value.410 www.ekja.org
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Ramosetron versus other antiemetics or combination 
therapy
As several trials compared ramosetron with other active 
drugs, combined data analysis was performed with respect to 
the route of administration (e.g. per oral and PCA), different 
time points of application (e.g. before and after induction), 
and different doses of active drugs (e.g. ondansetron and 
dexamethasone). Due to insufficient or missing appropriate 
data to combine or compare, no further analysis was conducted 
(Table 1). 
Adverse effects
Several trials reported adverse effects, including headache, 
dizziness, constipation/diarrhea, muscle pain, and drowsiness/
sedation. No weighting was used for different grades of adverse 
effects. Headache was the most often observed adverse effect, 
but all adverse events were transient and clinically insignificant. 
There were no severe adverse events, and no trials presented 
any statistically significant difference between ramosetron and 
placebo or granisetron. 
Discussion 
Despite extensive research and the introduction of 
ramosetron with better efficacy and safety profiles, there seems 
to be very few articles which assessed the drug using valid 
methods. In 18 RCTs, we observed a small number of patients 
suffering from PONV following administration of a fixed dose of 
0.3 mg ramosetron in adults and 6 μg/kg in children without any 
serious adverse effects. Such results indicate that ramosetron is 
an effective and well-accepted prophylactic antiemetic in early, 
late, and overall periods. Antiemetic effect in early and late POV 
and late POV were similar. In spite of significant differences 
between overall PONV and rescue-need, late PON did not 
show difference from placebo, which remains to be clarified. 
Ramosetron has a long half-life (5.8 h), and its antiemetic effect 
when given as an IV bolus lasted up to 48 h [22,27,28]. Several 
reports concluded 0.3 mg ramosetron is the minimum effective 
dose, and no more than 0.3 mg was needed in adults and 6 μg/
kg in children [5,20-26]. Addition of ondansetron to PCA or 8 
mg IV ondansetron was as effective as 0.3 mg ramosetron, and 
the same efficacy was observed with granisetron [28-33]. We 
need more data for combination therapy, as there is no report 
on any additive or synergic antiemetic effects of the combi-
nation of ramosetron with other active drugs. An optimal dose 
of combination therapy needs to be identified. 
Although this meta-analysis suggested that a dose of 0.3 mg 
ramosetron in adults and 6 μg/kg in children is effective and 
safe for the prevention of PONV, there are some issues to be 
addressed. Heterogeneity of combing results (I
2-test: 74%) from 
all relevant reports was revealed in overall PONV. Multi-factorial 
sources might be attributed to different types of surgery, 
anesthetic techniques, sex, age, and route and timing of drug 
administration. Subgroup analysis did not clearly exclude an 
underlying subtle risk factor to classify an interaction because 
of a different preoperative PONV risk profile of each trial. A 
significantly better antiemetic efficacy and safety of ramosetron 
in comparison with placebo was revealed in data analysis by 
age, timing of drug administration, and surgery type. 
Although responses to different prophylactic doses were 
not investigated due to insufficient data, a fixed dose of 0.3 
mg ramosetron in adults and 6 μg/kg in children seemed to 
be a rational option in practice in overall period. NNT 3.3 of 
overall PONV indicated that patients at risk of nausea and 
vomiting were likely to benefit by intervention of 0.3 mg 
ramosetron in adults and 6 μg/kg in children. This means 
that 1 in 3 patients who are suffering from nausea or vomiting 
and would otherwise continue to suffer with placebo will be 
prevented from further nausea and vomiting with ramosetron 
treatment. However, because of the small number of studies 
and participating subjects in early and late periods, this review 
could not give clear and real suggestions regarding the effect of 
the drug in each period. An insufficient number of reports on 
trials in children, combination therapy, and comparison with 
other active drugs could have potentially provided misleading 
information and thus require larger observational studies. 
The most frequently reported adverse effect was headache, 
and others were limited to dizziness, constipation/diarrhea, 
muscle pain, and drowsiness/sedation. There was no significant 
difference in adverse events between ramosetron and 
placebo or granisetron. The severity of the adverse effects was 
considered to be mild to moderate, and was resolved with no 
intervention. Ramosetron was judged as safe in this review.
This study has some limitations. First, there may be a 
publication bias although we tried to minimize it in the process 
of article selection. Publication bias shown by a funnel plot 
(Fig. 4) may alter the results of this review. In general, a positive 
result of trials may usually be easier to report than a negative 
one. Causes of other than publication bias should be made 
caution for any interpretation in funnel plot. Second, our result 
in overall PONV revealed heterogeneity despite the inclusion 
of 18 RCTs with 1888 patients, which limits drawing a general 
conclusion and providing any recommendation. Accordingly, 
a limited comparison was performed for a fixed dose of 0.3 mg 
ramosetron in adults and 6 μg/kg in children where possible. 
Third, there were a small number of trials on combination 
therapy and children, which limited the pooled analysis.
This review demonstrated that intervention with 0.3 mg 411 www.ekja.org
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ramosetron in adults and 6 μg/kg in children was highly 
efficacious and safe in surgical setting when applied before 
induction or at the end of surgery. Indeed, our result indicated 
that ramosetron provided potential clinical advantages with 
minimal adverse effects and reduced overall PONV after 
anesthesia in both adult and pediatric patients. The drug is 
a good alternative over existing drugs and prophylactics of 
PONV. However, available data were sparse and limited, and 
further trials are warranted to assess its effect on children, 
timing and route of application, comparisons with other active 
drugs, or combination therapy. Well-designed larger trials are 
needed to elucidate the relationship between ramosetron and a 
preoperative risk profile. 
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